魏國珍醫師於SNO神經腫瘤學會/FUS聚焦式超音波協會網路研討會中介紹最近臨床發現

 2020 年 10 月 13 日，SNO神經腫瘤學會/FUS基金會舉辦關於聚焦式超音波破壞血腦屏障（BBBD） 的網路研討會。 目前有多項計畫與正在進行的臨床試驗，在研究這種迅速發展的方法，來增強小分子、抗體和細胞向腦腫瘤的傳遞。

此網路研討聚集製藥公司及生物技術公司，提供研究人員們一起推動這項技術，以及有關使用聚焦式超音波破壞血腦屏障（BBBD）於腦腫瘤患者上的最新機會與挑戰資訊。 五位領域專家簡報，隨後進行問答討論。 


觀看更多>






Comments

Post a Comment

Popular posts from this blog

NaviFUS eyeing next year to launch new NAVIRFA Scope product in Taiwan and U.S. market

Image
 NaviFUS, a subsidiary of Genovate Biotech (4130), is developing a Radiofrequency Ablation (RFA) product called the NAVIRFA Scope. Simultaneous applications for regulatory approval are underway in both the United States and Taiwan.  NaviFUS has already submitted a pre-market notification 510(k) application to the U.S. FDA on December 4, 2020, and it expects to receive approval as early as mid-2021; at the same time, NaviFUS will also seek regulatory approval in Taiwan for the NAVIRFA Scope, and it has previously signed a sales distributor contract with UniPharma on October 31, 2020. NaviFUS believes that regulatory approval can also be acquired in 2021 and thus begin commercial sales in Taiwan.  There are approximately one million liver cancer patients worldwide, and the Asia-Pacific market has an annual growth rate of 12.67%; it is a market that urgently needs new treatment methods. In comparison with other first-line treatments such as surgery and hepatic artery embolization, RFA has
Read more

NaviFUS highlights clinical trial data and device capabilities at virtual International Focused Ultrasound Symposium

Image
 TAIPEI, Nov. 27, 2020 /PRNewswire/ -- The 7th International Focused Ultrasound Symposium organized by the U.S. Focused Ultrasound Foundation took place from 11/9 to 11/13 in virtual format this year due to the Covid-19 epidemic. During the 5-day conference, participants presented and exchanged information on the newest developments and applications of non-invasive Focused Ultrasound (FUS) technology. Likely the largest FUS event of the year, the virtual conference hosted over 1,700 industry, medical, and academic professionals from all over the world. NaviFUS was heavily involved in the virtual conference this year; posting 3 recorded oral presentations and 1 poster presentation, and also participating in 2 panel discussions during the first two days of the conference. Notable highlights from NaviFUS at the conference include its Epilepsy neuromodulation clinical trial that just finished its safety phase, preliminary progress from its FUS combined with Avastin in rGBM patients clinica
Read more